- Home
- Products
- Customized ADCs
- IL23A
- Anti-IL23A (Tildrakizumab)-MC-MMAF ADC
Anti-IL23A (Tildrakizumab)-MC-MMAF ADC (CAT#: ADC-W-1354)
This ADC product is comprised of an anti-IL23A monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL23A
- Alternative Names
- IL23A; interleukin 23, alpha subunit p19; interleukin-23 subunit alpha; IL 23; IL 23A; IL23P19; interleukin six; G CSF related factor; P19; SGRF; IL-23-A; IL-23p19; IL-23 subunit alpha; interleukin 23 p19 subunit; interleukin-23 subunit p19; JKA3 induced upon T-cell activation; interleukin-six, G-CSF related factor; IL-23; IL-23A; MGC79388;
- Target Entrez Gene ID
- 51561
- Target UniProt ID
- Q9NPF7
- Overview
- This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells.
- Overview
- Humanized Anti-IL23A IgG1-kappa antibody, Tildrakizumab
- Generic name
- Tildrakizumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-ST8SIA1 (Mitumomab)-SPDB-DM4 ADC (CAT#: ADC-W-1779)
- Anti-MS4A1-SPP-DM1 ADC (CAT#: ADC-W-617)
- Anti-TNFRSF8 (cAC10)-Mc-PABC-MMAE ADC (CAT#: ADC-W-342)
- Anti-AFP (Tacatuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-656)
- Anti-NRP1 (Vesencumab)-SMCC-DM1 ADC (CAT#: ADC-W-1676)
- Anti-TNFRSF10B (Tigatuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1881)
- Anti-CD4 (Tregalizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-876)
- Anti-IL17RA (Brodalumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1321)
- Anti-PCSK9 (Lodelcizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1688)
- Anti-ERBB2 (cFRP5)-MCC-DM1 ADC (CAT#: ADC-W-511)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1354. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1352 | Anti-IL23A (Tildrakizumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1355 | Anti-IL23A (Tildrakizumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1347 | Anti-IL23A (Guselkumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1346 | Anti-IL23A (Guselkumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1350 | Anti-IL23A (Guselkumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-478 | Anti-ENPP3-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-115 | Anti-CD33 (clone h2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2561 | Anti-MSLN (Anetumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
